Keros Therapeutics Inc (KROS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 405,863 | 442,443 | 331,147 | 287,893 | 322,026 |
| Receivables | 4 | 226 | 143 | N/A | N/A |
| TOTAL | $432,714 | $463,126 | $347,293 | $304,435 | $334,308 |
| Non-Current Assets | |||||
| PPE Net | 4,292 | 4,434 | 4,134 | 3,357 | 3,087 |
| Other Non-Current Assets | 18,016 | 18,259 | 18,598 | 18,455 | 18,911 |
| TOTAL | $22,308 | $22,693 | $22,732 | $21,812 | $21,998 |
| Total Assets | $455,022 | $485,819 | $370,025 | $326,247 | $356,306 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 6,535 | 4,986 | 5,450 | 3,867 | 4,146 |
| Accrued Expenses | 13,614 | 12,682 | 17,918 | 12,223 | 11,949 |
| TOTAL | $21,245 | $18,718 | $24,373 | $16,701 | $16,095 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 12,861 | 13,154 | 13,439 | 13,704 | 13,951 |
| TOTAL | $12,861 | $13,154 | $13,439 | $13,704 | $13,951 |
| Total Liabilities | $34,106 | $31,872 | $37,812 | $30,405 | $30,046 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 37,522 | 36,084 | 35,983 | 29,959 | 29,663 |
| Common Shares | 3 | 3 | 3 | 3 | 3 |
| Retained earnings | -469,797 | -424,540 | -381,426 | -341,183 | -301,743 |
| TOTAL | $420,916 | $453,947 | $332,213 | $295,842 | $326,260 |
| Total Liabilities And Equity | $455,022 | $485,819 | $370,025 | $326,247 | $356,306 |